AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones

Original post:
AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh